A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Purpose

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).

Conditions

  • Obesity
  • Overweight

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease - Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m² - Have had a self-reported stable weight for 3 months prior to screening

Exclusion Criteria

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data - Is an individual of childbearing potential (IOCBP)

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Part A: LY4174794 		Participants will receive LY4174794 administered subcutaneously (SC).
  • Drug: LY4174794
    Administered SC.
  • Drug: Placebo
    Administered SC.
Experimental
Part B: LY4174794 		Participants will receive LY4174794 administered SC.
  • Drug: LY4174794
    Administered SC.
  • Drug: Placebo
    Administered SC.
Placebo Comparator
Part A & B: Placebo 		Participants will receive placebo administered SC.
  • Drug: Placebo
    Administered SC.
Experimental
Part C: LY4174794 		Participants will receive LY4174794 administered intravenously (IV).
  • Drug: LY4174794
    Administered IV.

Recruiting Locations

ICON Early Phase Services, LLC
San Antonio, Texas 78232
Contact:
210-225-5437

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com